🔬Deep Research

ABUS — Arbutus Biopharma Corp · catalysts, narrative & risks

·14 sourcesABUS forecast →

Overview

Arbutus Biopharma Corp. (Nasdaq: ABUS) is a clinical-stage, virology-focused biopharmaceutical company headquartered in Warminster, Pennsylvania, pursuing a functional chronic hepatitis B (cHBV) cure and developing an oral PD-L1 inhibitor (AB-101) [6], [12], [13]. The following reflects the situation as of October 3, 2026. Note that one calendar item—the November 16, 2026 earnings release—comes from our own unverified tracking and should be treated as a lead to confirm [Calendar].

Recent Catalysts (July–October 2026)


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →